8β-vinyl-16α-fluoro-estra-1,3,5(10)-triene-3,17α-diol | 1099821-92-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 8β-vinyl-16α-fluoro-estra-1,3,5(10)-triene-3,17α-diol
• 英文别名: 16alpha-Fluor-8-vinyl-estra-1,3,5(10)-trien-3.17alpha-diol；(8S,9S,13S,14S,16R,17S)-8-ethenyl-16-fluoro-13-methyl-7,9,11,12,14,15,16,17-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 1099821-92-7
• 化学式: C₂₀H₂₅FO₂
• 分子量: 316.416
• InChiKey: SIZFLILRUOLMJK-UXXOSCIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-Methoxy-16a-fluor-8-vinyl-estra-1,3,5(10)-trien-17α-ol 在 三氯化硼 、 四丁基碘化铵 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以94%的产率得到8β-vinyl-16α-fluoro-estra-1,3,5(10)-triene-3,17α-diol
  参考文献：
  名称：

  EP2014672

  摘要：

  公开号：

文献信息

• 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS
  申请人：Peters Olaf

  公开号：US20090029957A1

  公开（公告）日：2009-01-29

  The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula I their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action in the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.

  该发明涉及一般式I的8β-取代的Estra-1,3,5(10)-三烯衍生物，其用作药物活性成分，在体外与大鼠前列腺雌激素受体制备物的亲和力高于与大鼠子宫雌激素受体制备物的亲和力，在体内与子宫相比，对卵巢具有优先作用。本发明还涉及这些新化合物的制备、治疗用途以及包含这些新化合物的制药处方形式。
• DRUG DELIVERY SYSTEM WITH STABILISING EFFECT
  申请人：Funke Adrian

  公开号：US20110052699A1

  公开（公告）日：2011-03-03

  A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) as a water-soluble matrix polymer; an active ingredient being a steroid in which the positions 6 and 7 of the steroidal skeleton are both a —CH 2 — residue; and said film matrix has a thickness of less than 300 μm.

  一种药物传递系统，也称为单剂量形式，包括一种薄的水溶性膜基质，其中所述的膜基质包括：a）一种聚乙烯醇-聚乙二醇嫁接共聚物（PVA-PEG嫁接共聚物）作为水溶性基质聚合物；b）一种活性成分，其中类固醇的骨架的位置6和7都是—CH2—残基；以及c）所述膜基质的厚度小于300微米。
• 8-beta-substituted estratrienes as selectively active estrogens
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2014672A1

  公开（公告）日：2009-01-14

  The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula I their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action in the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.

  本发明涉及通式 I 的 8β 取代雌甾-1,3,5(10)-三烯衍生物 它们在体外对大鼠前列腺雌激素受体制剂的亲和力高于对大鼠子宫雌激素受体制剂的亲和力，在体内对卵巢的作用优于对子宫的作用。
• 8-BETA-SUBSTITUTED 16.ALPHA.-FLUORO-ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2176282B1

  公开（公告）日：2012-08-22
• DRUG DELIVERY SYSTEM
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2358351A1

  公开（公告）日：2011-08-24